Oncologists weigh second-line options after ICI failure in metastatic ccRCC, spotlighting lenvatinib/everolimus, new agents, ...
Please provide your email address to receive an email when new articles are posted on . Patients with PBC and advanced fibrosis are not offered second-line therapy despite having “most to gain by ...
Continuing anti-vascular endothelial growth factor (VEGF) therapy plus chemotherapy in the second-line setting led to a small but nonsignificant increase in overall survival in patients with ...
Fast track status supports expedited development/review for a serious hematologic malignancy with limited second-line therapy after HMA failure. CyTAC engineering merges small-molecule CCR2 binding ...
Small cell lung cancer (SCLC) remains a highly aggressive malignancy with limited treatment options in the second-line setting, contributing to poor patient outcomes. Advances in therapeutic ...
Socioeconomic disparities in pancreatic cancer treatment: The role of pre-diagnosis healthcare utilization. Best overall responses (BOR) of third or above line subgroup or ECOG PS 2-3 subgroup. third ...
But it doesn't always end there. At some point, you may need to switch treatments. The growing number of options to manage HR-positive/HER2-negative metastatic breast ...
Epcoritamab addition to R2 significantly improves progression-free survival and overall response rates in relapsed follicular lymphoma. The EPCORE FL-1 trial results show a 79% progression-free ...
Cetuximab every second week in combination with daily encorafenib in patients with BRAF V600E mutated metastatic colorectal cancer: Interim analysis from NEW BEACON. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results